B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Publisher Name :
Date:31-Oct-2012
No. of pages: 52
Inquire Before Buying

B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
B-Cell Chronic Lymphocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 8
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies 10
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Development by Companies 15
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 17
Genzyme Corporation 17
Abbott Laboratories 18
GTC Biotherapeutics, Inc. 19
Ono Pharmaceutical Co., Ltd. 20
Alexion Pharmaceuticals, Inc. 21
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
samalizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Campath + Fludara - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
alvocidib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alvocidib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
alvocidib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alvocidib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABT-263 + Rituximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Leukapheresis + Fludarabine + Cyclophosphamide + Autologous CD19 Specific T-cell Infusion - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
cediranib maleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ABT-348 + Azacitidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ONO-4059 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-CD 19 CAR Autologous PBL - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 49
Featured News & Press Releases 49
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 49
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Genzyme Corporation, H2 2012 17
Abbott Laboratories, H2 2012 18
GTC Biotherapeutics, Inc., H2 2012 19
Ono Pharmaceutical Co., Ltd., H2 2012 20
Alexion Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Global Non-small Cell Lung Cancer Market 2014-2018
    Published: 10-Sep-2014        Price: US $2500 Onwards        Pages: 92
    Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is consi......
  • Burkitt Lymphoma – Pipeline Review, H2 2014
    Published: 10-Sep-2014        Price: US $2000 Onwards        Pages: 47
    Burkitt Lymphoma - Pipeline Review, H2 2014SummaryGlobal Markets Direct's, ‘Burkitt Lymphoma - Pipeline Review, H2 2014', provides an overview of the Burkitt Lymphoma's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and fe......
  • Uterine Cancer – Pipeline Review, H2 2014
    Published: 10-Sep-2014        Price: US $2000 Onwards        Pages: 66
    Uterine Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct's, ‘Uterine Cancer - Pipeline Review, H2 2014', provides an overview of the Uterine Cancer's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured n......
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 538
    Global Markets Direct's, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2014', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA)......
  • Cervical Cancer – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 236
    Global Markets Direct's, ‘Cervical Cancer Pipeline Review, H2 2014', provides an overview of the Cervical Cancer's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key playe......
  • OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma – Opportunity Analysis and Forecast to 2018
    Published: 25-Aug-2014        Price: US $7995 Onwards        Pages: 178
    OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018SummaryThe competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolv......
  • EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to 2023
    Published: 25-Aug-2014        Price: US $3995 Onwards        Pages: 43
    EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023SummaryRenal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC o......
  • Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM
    Published: 20-Aug-2014        Price: US $4995 Onwards        Pages: 105
    GBI Research, the leading business intelligence provider, has released its latest research, ""Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM"", which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with mark......
  • Global Hodgkins Lymphoma Therapeutics Market 2014-2018
    Published: 6-Aug-2014        Price: US $2500 Onwards        Pages: 79
    Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main trea......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs